The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

Recent advances in single-cell technologies, particularly single-cell RNA-sequencing
(scRNA-seq), have permitted high throughput transcriptional profiling of a wide variety of …

Glial fibrillary acidic protein (GFAP) is an intermediate filament protein that is characteristic
for astrocytes and neural stem cells, and their malignant analogues in glioma. Since the …

The limited efficacy of immunotherapies against glioblastoma underscores the urgency of
better understanding immunity in the central nervous system. We found that treatment with …

Intra-tumoral heterogeneity is a hallmark of glioblastoma that challenges treatment efficacy.
However, the mechanisms that set up tumor heterogeneity and tumor cell migration remain …

Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral
heterogeneity and tumor evolution. We utilized 3D neuronavigation during surgical resection …

Recent longitudinal studies of glioblastoma (GBM) have demonstrated a lack of apparent
selection pressure for specific DNA mutations in recurrent disease. Single-cell lineage …

Purpose: The abundance and biological contribution of cancer-associated fibroblasts (CAF)
in glioblastoma (GBM) are poorly understood. Here, we aim to uncover its molecular …

Glioblastoma (GBM) is characterized by extensive cellular and genetic heterogeneity. Its
initial presentation as primary disease (pGBM) has been subject to exhaustive molecular …

The highly widespread and infiltrative nature of glioblastoma multiforme (GBM) makes
complete surgical resection hard, causing high recurrence rate and poor patients' prognosis …